CPT PLA Reimbursement Code Approved in US for PromarkerD
ResearchDx and Proteomics International are pleased to announce the American Medical Association has approved a new dedicated CPT® Proprietary Laboratory Analyses (PLA) code for PromarkerD. This is a significant milestone and a key step toward future reimbursement coverage of the test by both Medicare and private health insurers in the United States. ASX Release
ResearchDx/Targeted Genomics receives FDA 510 (k) Clearance!
ResearchDx and Targeted Genomics are thrilled to announce that the GlutenID Celiac Genetic Health Risk Test has received FDA 510(k) clearance (K241456) with testing to be performed at ResearchDx’s PacificDx facility. Press Release Decision Summary @PacificDx
Proteomics International
Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), and ResearchDx DBA PacificDx proudly announce ProMarkerD, the groundbreaking predictive test for diabetic kidney disease. This innovative test empowers clinicians and patients by enabling early intervention to slow or prevent kidney function decline. Press Release @PromarkerD
Visit ResearchDx at ASCO Booth 15036
The 2025 ASCO (American Society of Clinical Oncology) Annual Meeting is the largest global oncology conference, taking place in Chicago, IL, from May 30 to June 3. It features over 200 interactive sessions, including presentations on the latest research and policy updates across all areas of oncology. Read More
HistoIndex
FibroSIGHT™ is Here: A New Standard in Clinical Care of MASH Patients. FibroSIGHT enables sensitive detection and visualization of MASH liver fibrosis, eliminating the variability associated with traditional staining techniques. Read More @PacificDx
Prostatype Genomics
Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market for their groundbreaking Prostatype Gene Test Read More @Prostatype Genomics @PacificDx
Heranova
Heranova announces succesful CLIA certification and Early access launch of their groundbreaking HerResolve™, a Potential First FDA-Cleared, Non-Invasive Endometriosis Test Read More
Vesica Health
Vesica Health Announces Launch of AssureMDx Test to Improve Bladder Cancer Detection Read More @Vesicahealth